Sign In
Buy TXG
$47.27
-2.16 (-4.37%)
At Close: Jul 31, 2026
Better Buy: 10x Genomics vs. DermTech
07:15am, Thursday, 11'th Nov 2021
Both companies offer disruptive new solutions in their niches of the healthcare space.
10x Genomics Clocks 74% Jump In Q3 Revenues; Raises Top End Of Sales Guidance
07:41am, Thursday, 04'th Nov 2021
10x Genomics Inc (NASDAQ: TXG) reported Q3 sales of $125.3 million, beating the consensus of $122.62 million. Sales increased 74% Y/Y, primarily due to increased consumables revenue driven by growth
10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates
07:53pm, Wednesday, 03'rd Nov 2021
10x Genomics (TXG) delivered earnings and revenue surprises of 16.67% and 0.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics Earnings Preview
11:28am, Tuesday, 02'nd Nov 2021
10x Genomics (NASDAQ:TXG) is set to give its latest quarterly earnings report on Wednesday, 2021-11-03. Here's what investors need to know before the announcement.
Wall Street Analysts See a 27% Upside in 10x Genomics (TXG): Can the Stock Really Move This High?
01:01pm, Wednesday, 13'th Oct 2021
The mean of analysts' price targets for 10x Genomics (TXG) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among anal
10x Genomics to Report Third Quarter Financial Results on November 3, 2021
04:05pm, Thursday, 07'th Oct 2021
PLEASANTON, Calif., Oct. 7, 2021 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3rd,
Why 10x Genomics Shares Are Trading Lower Today
03:31pm, Tuesday, 14'th Sep 2021
10x Genomics (NASDAQ:TXG) shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral and announced a $180 price target. 10x Genomics' stock is currently down 7.53% to a
10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
04:05pm, Tuesday, 31'st Aug 2021
PLEASANTON, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference
BIGZ: A Long-Term Income Investment With Some Growth Opportunity
05:23am, Tuesday, 31'st Aug 2021
BIGZ: A Long-Term Income Investment With Some Growth Opportunity
10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit
08:00am, Friday, 06'th Aug 2021
PLEASANTON, Calif., Aug. 06, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summi
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q2 2021 Results - Earnings Call Transcript
11:21pm, Wednesday, 04'th Aug 2021
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q2 2021 Results - Earnings Call Transcript
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
07:50pm, Wednesday, 04'th Aug 2021
10x Genomics (TXG) delivered earnings and revenue surprises of 61.54% and 2.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad
06:30am, Tuesday, 27'th Jul 2021
Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes
10x Genomics to Report Second Quarter Financial Results on August 4, 2021
04:03pm, Wednesday, 07'th Jul 2021
PLEASANTON, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the second quarter 2021 after market close on Wednesday, August 4t
These 3 Cathie Wood Stocks Are Still Going Strong
05:35am, Friday, 25'th Jun 2021
Even with some setbacks in 2021, the ARK Invest manager has still found some winners.
